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of selecting treatment options that may help reduce the risk of
relapse.
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OBJECTIVES: This study quantiﬁes direct health care costs of
schizophrenia patients in the US in 2002, as compared to a
demographically matched control sample. METHODS: Annual
excess health care costs of patients with schizophrenia were esti-
mated for both privately and publicly insured patients. Costs
were estimated using insurance and patient out-of-pocket
payment for patients with at least one schizophrenia diagnosis.
Patients were identiﬁed from two databases: a de-identiﬁed
employer claims database of ~3.0 million beneﬁciaries
(1999–2003) for privately insured patients (n = 1,090), and
Medi-Cal paid claims (2000–2003) for Medicaid patients (n =
14,074). Medicare costs were imputed using Medicare/Medi-Cal
dual eligible patients (n = 6887). Non-schizophrenia controls
were randomly matched to schizophrenia patients in a 3 :1 ratio,
by demographic characteristics (i.e., age, gender, region of resi-
dence). Excess costs were estimated by comparing the costs of
schizophrenia patients to those of controls. Costs were adjusted
to 2002 dollars using the Medical Care CPI. California Medicare
and Medicaid beneﬁciary costs were extrapolated to the U.S.
using published per enrollee costs. Schizophrenia prevalence 
was based on analysis of the National Comorbidity Survey 
Replication (NCS-R) and other epidemiological literature.
RESULTS: The total excess health care costs of the schizophre-
nia population were estimated at about $16.3 billion, with $7.2
billion from outpatient costs, $4.6 billion from drug costs, 
$2.6 billion from hospital inpatient costs, and $1.9 billion from
long term care costs. CONCLUSIONS: A comparison of these
results with previous schizophrenia studies suggests a shift 
from inpatient to outpatient and drug costs in the past decade.
Since 1991, the proportion of total direct health care costs at-
tributable to inpatient services decreased by approximately 
40%. The proportion of costs attributable to drugs and out-
patient costs increased by approximately 28% and 37% res-
pectively. This shift suggests that new effective pharmaceuticals
may lead to potential cost savings through avoiding expensive
hospitalizations.
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OBJECTIVES: This retrospective claims-based study compared
atypical antipsychotics to typical antipsychotics and to each
other with respect to risk of hospitalization and inpatient costs
among Ohio Medicaid patients with schizophrenia. METHODS:
Relative risks of hospitalization for mental illness between
enrollees with diagnosed schizophrenia treated with any of the
atypical antipsychotics (risperidone, olanzapine, quetiapine,
ziprasidone) or any of the leading traditional antipsychotics
(haloperidol, perphenazine, thioridazine, thiothixene) were
assessed. Cox proportional hazard regression controlled for age,
gender, diagnosis, prior hospitalization and ER use, substance
dependence/abuse, antipsychotic dose, use of other psychotrop-
ics, and other health needs. Differences in length of stay and
inpatient costs (charges) were also assessed. RESULTS: Patients
treated with quetiapine had a 33% lower risk of hospitalization
for mental illness compared with patients treated with typical
antipsychotics (HR 0.672; P = 0.0413), equating to $389 lower
expected annual inpatient charges per patient for quetiapine.
Other pair-wise comparisons of antipsychotic-related hospital-
ization were not statistically signiﬁcant. Risperidone was associ-
ated with signiﬁcantly longer hospital stays than the typicals
(1.78, P = 0.0301), resulting in $303 higher expected annual
inpatient charges per patient. Risperidone also had signiﬁcantly
longer lengths of stay than olanzapine, 1.88 days (P = 0.006),
resulting in higher inpatient charges ($320 annual per patient).
Other differences in length of stay were not signiﬁcant at P <
0.05. CONCLUSIONS: Quetiapine was associated with a 
lower risk of hospitalization for mental illness compared with
typical antipsychotics, resulting in substantially lower inpatient
charges. While risperidone may also have a lower risk of hospi-
talization than the typicals (22% lower, ns P = 0.0932), length
of stay was signiﬁcantly longer, contributing to higher inpatient
charges. Risperidone also had signiﬁcantly longer lengths of stay
than olanzapine with associated higher inpatient costs, and may
also have longer stays than ziprasidone (3.61 days, ns P =
0.0619).
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OBJECTIVES: Patient adherence to medications can be
improved by proper identiﬁcation of patients at risk for non-
adherence. This study aims to classify patients to latent non-
adherence casemix classes varying in degree of adherence, and
to examine the socio-demographic and clinical correlates of class
memberships. METHODS: We used patients (n = 36,195) with
a schizophrenia diagnosis from the 100%-sample Medi-Cal fee-
for-service paid claims data (1999~2003). The date of the ﬁrst
antipsychotic medication (index date) was used to deﬁne a 6-
month pre-index and a 12-month post-index periods. Latent
class analysis was applied to four categorical adherence indica-
tors: a dichotomous variable derived from medication possession
ratio (MPR; cut-off = 0.8); number of treatment attempts (1, 2,
3, 4, > 4), duration of uninterrupted therapy (<30, 30~60,
60~120, 120~240, 240~365, >365 days); and time to ﬁrst
switching of medication (no switching, <30, 30~90, 90~180,
180~365 days). Determinants and consequences of non-adher-
ence were examined by proﬁling each latent class in terms of
covariates and utilization outcomes. RESULTS: Models with up
to ﬁve classes were explored, leading to a ﬁnal selection of three
classes: adherent (prevalence 14.9%), partially adherent (28.1%)
and non-adherent (57.0%) based on the smallest classiﬁcation
error (2.14%). Non-adherent class was associated with minor-
ity ethnicity, more suicide attempts, more hospitalizations and
inpatient rehabilitations than other classes. Partially adherent
class displayed higher outpatient care use, higher depot antipsy-
chotic drugs, and higher rate of polypharmacy. Adherent class
displayed the exact opposite characteristics as non-adherent
class. Total costs in the 12-month follow-up period were $9,370
